Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Fong

Showing results (81-90 of 198) with videos related to

Pageof 20
Sort By:
Cell|April 6, 2019
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and MemoryMauro Poggio, Tianyi Hu, Chien-Chun Pai, et al.
Cancer Immunology, Immunotherapy : CII|April 17, 2021
Tumor morphology and location associate with immune cell composition in pleomorphic sarcomaRosanna L Wustrack, Evans Shao, Joey Sheridan, et al.
Cancer Immunology Research|May 14, 2015
Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with IpilimumabSerena S Kwek, Jera Lewis, Li Zhang, et al.
Cancer Cell|December 15, 2021
Toward a better understanding of T cells in cancerDavid Y Oh, Lawrence Fong, Evan W Newell, et al.
Science Translational Medicine|April 7, 2010
Identification of an autoantigen demonstrates a link between interstitial lung disease and a defect in central toleranceAnthony K Shum, Jason DeVoss, Catherine L Tan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2019
Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate CancerDouglas G McNeel, Jens C Eickhoff, Laura E Johnson, et al.
Bioconjugate Chemistry|September 20, 2018
A Preclinical Assessment of <sup>89</sup>Zr-atezolizumab Identifies a Requirement for Carrier Added Formulations Not Observed with <sup>89</sup>Zr-C4Anna Moroz, Chia-Yin Lee, Yung-Hua Wang, et al.
The Oncologist|March 1, 2018
A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate CancerXiao X Wei, Adam P Siegel, Rahul Aggarwal, et al.
Oncoimmunology|May 4, 2016
GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responsesSerena S Kwek, James Kahn, Samantha K Greaney, et al.
Journal for Immunotherapy of Cancer|April 3, 2025
Impact of tumor localization on antitumor immunity with conditionally activated CTLA-4 blockadeMarcel Arias-Badia, Chien-Chun Steven Pai, Yee May Lwin, et al.
Pageof 20

Showing results (81-90 of 198) with videos related to

Sort By:
Pageof 20
Cell|April 6, 2019
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and MemoryMauro Poggio, Tianyi Hu, Chien-Chun Pai, et al.
Cancer Immunology, Immunotherapy : CII|April 17, 2021
Tumor morphology and location associate with immune cell composition in pleomorphic sarcomaRosanna L Wustrack, Evans Shao, Joey Sheridan, et al.
Cancer Immunology Research|May 14, 2015
Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with IpilimumabSerena S Kwek, Jera Lewis, Li Zhang, et al.
Cancer Cell|December 15, 2021
Toward a better understanding of T cells in cancerDavid Y Oh, Lawrence Fong, Evan W Newell, et al.
Science Translational Medicine|April 7, 2010
Identification of an autoantigen demonstrates a link between interstitial lung disease and a defect in central toleranceAnthony K Shum, Jason DeVoss, Catherine L Tan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2019
Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate CancerDouglas G McNeel, Jens C Eickhoff, Laura E Johnson, et al.
Bioconjugate Chemistry|September 20, 2018
A Preclinical Assessment of <sup>89</sup>Zr-atezolizumab Identifies a Requirement for Carrier Added Formulations Not Observed with <sup>89</sup>Zr-C4Anna Moroz, Chia-Yin Lee, Yung-Hua Wang, et al.
The Oncologist|March 1, 2018
A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate CancerXiao X Wei, Adam P Siegel, Rahul Aggarwal, et al.
Oncoimmunology|May 4, 2016
GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responsesSerena S Kwek, James Kahn, Samantha K Greaney, et al.
Journal for Immunotherapy of Cancer|April 3, 2025
Impact of tumor localization on antitumor immunity with conditionally activated CTLA-4 blockadeMarcel Arias-Badia, Chien-Chun Steven Pai, Yee May Lwin, et al.
Pageof 20